10-Q: Myriad Genetics Q3 2026: Revenue Dip, Strategic Divestiture

Sentiment:

Quarterly Report


Myriad Genetics reports a revenue decrease for Q3 2026, driven by a decline in Prenatal Health, while preparing to sell its Prenatal Health business for $210 million.

Worse than expectedRevenue for the three months ended September 30, 2026, decreased by $3.0 million compared to the prior year period.Revenue for the nine months ended September 30, 2026, decreased by $20.9 million compared to the prior year period.Net loss for the three months ended September 30, 2026, increased to $43.9 million from $27.4 million in the prior year period.Sales and marketing expenses increased by $12.9 million in the three months ended September 30, 2026, compared to the prior year period.

Summary

  • Myriad Genetics reported a net loss of $43.9 million for the third quarter of 2026, compared to a net loss of $27.4 million in the same period of 2025.
  • Total revenue for the third quarter of 2026 was $202.7 million, a decrease from $205.7 million in the third quarter of 2025.
  • For the nine months ended September 30, 2026, total revenue was $593.8 million, down from $614.7 million in the same period of 2025.
  • The company announced an agreement to sell its Prenatal Health business for $210 million, expected to close by early 2027.
  • Operating expenses increased in the third quarter of 2026, primarily due to higher sales and marketing expenses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to declining revenues in key segments, increased operating expenses, and a significant goodwill impairment charge in the prior year, despite a planned divestiture.

Positives

  • The company has entered into an agreement to sell its Prenatal Health business for $210 million, which is expected to provide significant cash proceeds.
  • Cancer Care Continuum revenue saw a slight increase of $1.4 million in Q3 2026 compared to Q3 2025, driven by a 4% increase in volume.
  • Mental Health revenue increased by $0.8 million in Q3 2026 compared to Q3 2025, also driven by a 3% increase in volume.
  • Research and development expenses remained relatively consistent year-over-year for both the three and nine-month periods.
  • General and administrative expenses decreased by $0.7 million in Q3 2026 compared to Q3 2025.

Negatives

  • Total revenue decreased by $3.0 million in Q3 2026 compared to Q3 2025, primarily due to a $5.2 million decrease in Prenatal Health revenue.
  • Prenatal Health revenue decreased by $20.4 million for the nine months ended September 30, 2026, due to an 11% decrease in volume and a 4% decrease in revenue per test.
  • Cost of revenue increased by $3.1 million in Q3 2026 compared to Q3 2025.
  • Sales and marketing expenses increased significantly by $12.9 million in Q3 2026 compared to Q3 2025, representing an 18% increase.
  • Net loss for Q3 2026 was $43.9 million, an increase from $27.4 million in Q3 2025.

Risks

  • The sale of the Prenatal Health business may not be completed on the anticipated terms or timeline, or at all.
  • The pendency of the sale, or any failure to complete the Transaction, could adversely affect the company's business, financial condition, and stock price.
  • The company may not realize the anticipated benefits of the sale of the Prenatal Health business and may retain certain liabilities.
  • Following the sale of the Prenatal Health business, the company will have a lower overall revenue base, potentially impacting compliance with revenue covenants under its Credit Facility.
  • Third-party payors are increasingly limiting or denying coverage for tests and reducing reimbursement rates, which could impact future revenue.
  • Increased competition and the development of new competing tests pose a risk to market share and profitability.
  • The company may not be able to develop or achieve commercial success for additional tests in a timely manner.
  • Risks related to cybersecurity breaches, loss of data, and other disruptions, including from cyberattacks.

Future Outlook

The company intends to use the net proceeds from the sale of its Prenatal Health business for general corporate purposes, which may include repaying debt, funding operations, and investing in its Cancer Care Continuum business. Management believes that existing capital resources will be sufficient to meet projected operating requirements for at least the next 12 months.

Management Comments

  • We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
  • Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine.
  • Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum market with a priority for high growth applications; (ii) growing our Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model.
  • We are committed to making molecular testing accessible and actionable for patients and providers while driving long-term growth and profitability.

Industry Context

StockSavvy.ai notes that Myriad Genetics operates in the highly competitive and rapidly evolving molecular diagnostics and precision medicine sector. The company's strategy to focus on Cancer Care Continuum and Mental Health while divesting its Prenatal Health business reflects a common industry trend of portfolio optimization to concentrate on higher-growth or more profitable segments.

Comparison to Industry Standards

  • The company's revenue decline in Prenatal Health, despite growth in other segments, contrasts with some competitors who may be experiencing growth in similar areas.
  • The significant increase in sales and marketing expenses, while aimed at commercial expansion, is a substantial investment that needs to yield returns comparable to industry benchmarks for customer acquisition costs.
  • The goodwill impairment charge in the prior year highlights potential challenges in integrating acquisitions or valuing intangible assets, an area where industry leaders often demonstrate more stable performance.
  • The company's focus on specific market segments like Cancer Care Continuum and Mental Health aligns with industry trends towards specialization and targeted therapeutic areas.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Executive Vice President, CommercialN/AVishal Sikri2026-09-16Appointment

Legal Proceedings

  • A qui tam lawsuit filed under the False Claims Act against Carolina Urology Partners, PLLC, certain of its physician partners, and the Company and certain former employees, alleging violations of the False Claims Act. The government declined to intervene, and the Company's motion to dismiss was denied except for one count.
  • Patent infringement lawsuit filed by GXD-Bio Corporation against the Company and certain subsidiaries concerning the EndoPredict Test. The Unified Patent Court ruled the test does not infringe and the patent is invalid, but GXD has appealed this decision.

Stakeholder Impact

  • Shareholders may be impacted by the declining revenue and increased net loss, although the sale of the Prenatal Health business could provide a positive cash infusion.
  • Employees may be affected by the sale of the Prenatal Health business and the company's strategic focus on other segments.
  • Providers and payors will continue to be key stakeholders, with the company aiming to integrate its testing solutions into clinical workflows.
  • Creditors may be impacted by the company's use of proceeds from the sale, potentially including debt repayment.

Next Steps

  • Complete the sale of the Prenatal Health business to Laboratory Corporation of America.
  • Utilize net proceeds from the sale for general corporate purposes, including potential debt repayment, funding operations, and investment in the Cancer Care Continuum business.
  • Continue to focus on growth in the Cancer Care Continuum and Mental Health markets.
  • Manage operating expenses and maintain financial and operational discipline.

Key Dates

DateDescription
2025-07-31Company entered into Credit Agreement.
2026-01-05First Amendment to Credit Agreement entered into.
2026-03-31Goodwill impairment charge of $4.5 million recognized.
2026-06-04Stockholders approved the 2026 Employee, Director and Consultant Equity Incentive Plan.
2026-09-30End of the quarterly period for this Form 10-Q filing.
2026-10-19Company entered into definitive agreement to sell certain assets and liabilities of its Prenatal Health business.
2026-11-06Date of the Form 10-Q filing.
2027-02-19Termination date for the Prenatal Health business sale agreement if not closed.

Recommendation

hold

The company is undergoing a significant strategic shift with the divestiture of its Prenatal Health business, which is a positive step for cash generation. However, declining revenues in key segments, increased operating expenses, and a history of impairment charges suggest caution. While the focus on Cancer Care Continuum and Mental Health is strategic, the immediate financial performance indicates a 'hold' position until the benefits of the divestiture and strategic focus become clearer.

Keywords

molecular diagnostics, precision medicine, genetic testing, Cancer Care Continuum, Mental Health, Prenatal Health, revenue, net loss

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.